- Email: [email protected]
Fibrinolytic activity in patients with chronic renal failure
S196
ABSTRACTS OF 12TH INTNAT’L CONGRESS
Vol. 65, Suppi. 1
P386 FIBRINOLYTK ACTIVITY IN PATIENTS WITH CHRONIC RENAL FAILURE E Meriane, L. Badereddinne, S. Benbrahim, R. Hassen-Khodja CTS CHU Bab el Oued, ALGIERS, DZ Thirty-two patients with chronic renal failure were studied: 19 patients with mainteoed hemodialysis (PMH) and I3 patients under peritoneal dialysis (PPD) were tested. The duration of the dialysis was at least two years. The PMH were received an average of 7000 IU heparin for each dialysis. The blood sample was taken out before and after hemodialysis and the venous occlusion (VO) was performed immediately prior hemodialysis in 8 PMH. The data showed in one hand that the ECLT expressed as fibrinolytic activity (FA) was decreased in the two groups by opposite to the control group (19+8 for PMH; 15+ IO for PPD vs 35+9). However the hemodialysis induced an enhancing of FA to the near control value (33+ 12). The PA1 activity was very high (78+43 lU/ml vs I .9+ I .7 IU/ml) but the TPA antigen was enhanced after hemodiatysis (11.5+5.7 @ml vs 5.4+2 @ml) in the PMH while it was normal in PPD (4.1+3.3 nglml). In the other hand the VO induced an increasing of AT111 activity (76+21% before VO and 131 +I0 aRer VO); TPA (2.3+0.7 rig/ml before VO, 8+3.5 rig/ml after VO). In conclusion, the abnormal tibrinolytic activity could be related to the high PAI level either prior and after VO.
P387 INHIBITORS OF FIBRINOLYSIS UNDER rHuEP0 THERAPY IN URAEMlC M. MySliwiec, K. Pawlak, J. Malysxko, M. Maxerska, J. Malysxko Nephrology Department, Bialystok Medical School, PL Treatment with recombinant human erythropoietin (rHuEP0) may predispose to the increased frequency of thrombotic events in uraemic patients. Therefore we studied plasma tibrinolytic inhibitors in chronically haemodialyzed patients undergone erythropoietin therapy. Plasminogen activator inhibitor (PAI), alpha, antiplasmin (alpha, AP), antithrombin 111 (AT Ill), Cl esterase inhibitor (Cl INA) activities were studied using chromogenic substrates. Alpha, macrogiobulin concentration (alpha, M) (rocket immunoeiectrophoresis) as well as haematocrit were also measured before and aRer I, 2,4,8 and 12 weeks of rHuEP0 treatment in 22 patients with end-stage renal failure. After each haemodialysis rHuEP0 (Eprex, CiIag) in a dose of 2000 IU was given subcutaneously three times a week. The haematocrit was found to be increased starting from the 2nd week of the therapy. The changes were statistically significant and lasted throughout the therapy. PAI activity showed a significant fall after 1 week of rHuEP0 administration (p < 0.05) and remained decreased during the following weeks. Alpha, AP activity fell in the same manner with the most pronounced fall after I2 weeks. AT 111followed the same pattern with the lowest value after 4 weeks. The activity of Cl INH was slightly diminished. The lowest values were detected after 4 and I2 weeks of rHuEP0 therapy. There were no statistically significant changes in alpha, M concentration during rHuEP0 treatment. Low AT III activity in patients treated with erythropoietin may promote thrombosis. On the other hand a decreased plasma activity of other inhibitors of tibrinolysis may be a protective mechanism.
ABSTRACTS OF 12TH INTNAT’L CONGRESS
Vol. 65, Suppi. 1
P386 FIBRINOLYTK ACTIVITY IN PATIENTS WITH CHRONIC RENAL FAILURE E Meriane, L. Badereddinne, S. Benbrahim, R. Hassen-Khodja CTS CHU Bab el Oued, ALGIERS, DZ Thirty-two patients with chronic renal failure were studied: 19 patients with mainteoed hemodialysis (PMH) and I3 patients under peritoneal dialysis (PPD) were tested. The duration of the dialysis was at least two years. The PMH were received an average of 7000 IU heparin for each dialysis. The blood sample was taken out before and after hemodialysis and the venous occlusion (VO) was performed immediately prior hemodialysis in 8 PMH. The data showed in one hand that the ECLT expressed as fibrinolytic activity (FA) was decreased in the two groups by opposite to the control group (19+8 for PMH; 15+ IO for PPD vs 35+9). However the hemodialysis induced an enhancing of FA to the near control value (33+ 12). The PA1 activity was very high (78+43 lU/ml vs I .9+ I .7 IU/ml) but the TPA antigen was enhanced after hemodiatysis (11.5+5.7 @ml vs 5.4+2 @ml) in the PMH while it was normal in PPD (4.1+3.3 nglml). In the other hand the VO induced an increasing of AT111 activity (76+21% before VO and 131 +I0 aRer VO); TPA (2.3+0.7 rig/ml before VO, 8+3.5 rig/ml after VO). In conclusion, the abnormal tibrinolytic activity could be related to the high PAI level either prior and after VO.
P387 INHIBITORS OF FIBRINOLYSIS UNDER rHuEP0 THERAPY IN URAEMlC M. MySliwiec, K. Pawlak, J. Malysxko, M. Maxerska, J. Malysxko Nephrology Department, Bialystok Medical School, PL Treatment with recombinant human erythropoietin (rHuEP0) may predispose to the increased frequency of thrombotic events in uraemic patients. Therefore we studied plasma tibrinolytic inhibitors in chronically haemodialyzed patients undergone erythropoietin therapy. Plasminogen activator inhibitor (PAI), alpha, antiplasmin (alpha, AP), antithrombin 111 (AT Ill), Cl esterase inhibitor (Cl INA) activities were studied using chromogenic substrates. Alpha, macrogiobulin concentration (alpha, M) (rocket immunoeiectrophoresis) as well as haematocrit were also measured before and aRer I, 2,4,8 and 12 weeks of rHuEP0 treatment in 22 patients with end-stage renal failure. After each haemodialysis rHuEP0 (Eprex, CiIag) in a dose of 2000 IU was given subcutaneously three times a week. The haematocrit was found to be increased starting from the 2nd week of the therapy. The changes were statistically significant and lasted throughout the therapy. PAI activity showed a significant fall after 1 week of rHuEP0 administration (p < 0.05) and remained decreased during the following weeks. Alpha, AP activity fell in the same manner with the most pronounced fall after I2 weeks. AT 111followed the same pattern with the lowest value after 4 weeks. The activity of Cl INH was slightly diminished. The lowest values were detected after 4 and I2 weeks of rHuEP0 therapy. There were no statistically significant changes in alpha, M concentration during rHuEP0 treatment. Low AT III activity in patients treated with erythropoietin may promote thrombosis. On the other hand a decreased plasma activity of other inhibitors of tibrinolysis may be a protective mechanism.